Released: Saturday 1st October 2022

This £1.6m funding – led by Archangels, alongside Scottish Enterprise and Old College Capital – will enable the development and qualification of Cytomos Dielectric Spectroscopy (CDSTM) to move forward at pace and address the biopharma industry’s unmet needs.

Enabling non-specialists to perform quantitative and qualitative cytometry without typical cell labelling reagents will help unlock multiple markets with very high growth potential. Analysts estimate the value of the global market for single-cell analysis is expected to reach $6.3 billion by 2026.

“On behalf of our Board and employees I would like to thank our investors for their continued support of Cytomos. We now have the growth capital required to advance the development of our novel process analytical technology platform to the next phase of prototype evaluation with our strategic partners. This is an important milestone in the journey to deliver our mission to enable the development and manufacture of life-saving biologic therapies.”

Dr. Alan Raymond,
Executive Chairman, Cytomos